The Application of Nitric Oxide for Ocular Hypertension Treatment

Despite of various therapeutic methods for treating ocular hypertension and glaucoma, it still remains the leading cause of irreversible blindness. Intraocular pressure (IOP) lowering is the most effective way to slow disease progression and prevent blindness. Among the ocular hypotensive drugs currently in use, only a couple act on the conventional outflow system, which is the main pathway for aqueous humor outflow and the major lesion site resulting in ocular hypertension. Nitric oxide (NO) is a commendable new class of glaucoma drugs that acts on the conventional outflow pathway. An increasing number of nitric oxide donors have been developed for glaucoma and ocular hypertension treatment. Here, we will review how NO lowers IOP and the types of nitric oxide donors that have been developed. And a brief analysis of the advantages and challenges associated with the application will be made. The literature used in this review is based on Pubmed database search using ‘nitric oxide’ and ‘glaucoma’ as key words.

Download Full-text

Exogenous NO Therapy for the Treatment and Prevention of Atherosclerosis

International Journal of Molecular Sciences ◽

10.3390/ijms21082703 ◽

2020 ◽

Vol 21 (8) ◽

pp. 2703 ◽

Cited By ~ 3

Author(s):

Tommaso Gori

Keyword(s):

Nitric Oxide ◽

Endothelial Dysfunction ◽

Plaque Rupture ◽

Nitric Oxide Donors ◽

New Class ◽

Amyl Nitrite ◽

Treatment And Prevention ◽

The Subject ◽

Prevention Of Atherosclerosis ◽

Nitric Oxide Pathway

Amyl nitrite was introduced in 1867 as the first molecule of a new class of agents for the treatment of angina pectoris. In the following 150 years, the nitric oxide pathway has been the subject of a number of pharmacological approaches, particularly since when this elusive mediator was identified as one of the most important modulators of vascular homeostasis beyond vasomotion, including platelet function, inflammation, and atherogenesis. While having potent antianginal and antiischemic properties, however, nitric oxide donors are also not devoid of side effects, including the induction of tolerance, and, as shown in the last decade, of oxidative stress and endothelial dysfunction. In turn, endothelial dysfunction is itself felt to be involved in all stages of atherogenesis, from the development of fatty streaks to plaque rupture and thrombosis. In the present review, we summarize the agents that act on the nitric oxide pathway, with a particular focus on their potentially beneficial antiatherosclerotic and unwanted pro-atherosclerotic effects.

Download Full-text

A new class of nitric oxide donors

Herald of the Russian Academy of Sciences ◽

10.1134/s1019331616030096 ◽

2016 ◽

Vol 86 (3) ◽

pp. 158-163 ◽

Cited By ~ 10

Author(s):

S. M. Aldoshin ◽

N. A. Sanina ◽

M. I. Davydov ◽

E. I. Chazov

Keyword(s):

Nitric Oxide ◽

Nitric Oxide Donors ◽

New Class

Download Full-text

O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma

Chemical Communications ◽

10.1039/c7cc00213k ◽

2017 ◽

Vol 53 (36) ◽

pp. 5059-5062 ◽

Cited By ~ 6

Author(s):

Chengfeng Bai ◽

Rongfang Xue ◽

Jianbing Wu ◽

Tian Lv ◽

Xiaojun Luo ◽

...

Keyword(s):

Nitric Oxide ◽

Nitric Oxide Donor ◽

Nitric Oxide Donors ◽

New Class

3c, a new nitric oxide donor activatable by GSH/GSTπ, exhibits both anti-proliferative and anti-metastatic activities against melanoma.

Download Full-text

Correction: O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma

Chemical Communications ◽

10.1039/d0cc90145h ◽

2020 ◽

Vol 56 (29) ◽

pp. 4130-4131

Author(s):

Chengfeng Bai ◽

Rongfang Xue ◽

Jianbing Wu ◽

Tian Lv ◽

Xiaojun Luo ◽

...

Keyword(s):

Nitric Oxide ◽

Nitric Oxide Donors ◽

New Class

Correction for ‘O2-(6-Oxocyclohex-1-en-1-yl)methyl diazen-1-ium-1,2-diolates: a new class of nitric oxide donors activatable by GSH/GSTπ with both anti-proliferative and anti-metastatic activities against melanoma’ by Chengfeng Bai et al., Chem. Commun., 2017, 53, 5059–5062.

Download Full-text

In VivoNear-Infrared Fluorescence Imaging of Aqueous Humor Outflow Structures

Journal of Ophthalmology ◽

10.1155/2016/8706564 ◽

2016 ◽

Vol 2016 ◽

pp. 1-6 ◽

Cited By ~ 4

Author(s):

L. Zeppa ◽

L. Ambrosone ◽

G. Guerra ◽

M. Fortunato ◽

C. Costagliola

Keyword(s):

Primary Open Angle Glaucoma ◽

Open Angle Glaucoma ◽

High Viscosity ◽

Scleral Flap ◽

Clinical Trial Registration ◽

Aqueous Humor Outflow ◽

Retrograde Filling ◽

Outflow Pathway ◽

Aqueous Outflow ◽

Outflow System

The aim of this study has been to visualize the aqueous outflow system in patients affected by primary open angle glaucoma. A solution of indocyanine green (ICG) plus high viscosity viscoelastic solution was injected into the Schlemm canal during surgery in 10 glaucomatous patients undergoing canaloplasty. Soon after injection of the dye the borders of the scleral flap were completely stained due to partial reflux caused by the intrachannel resistance; progression of the dye along the Schlemm canal starting from the site of injection was then visualized. The filling of the collector channels was observed only in the patent portions of the Schlemm canal. The only noticeable aqueous veins were located in correspondence of the quadrant in which both the Schlemm canal and the collectors were patent. Lastly, a retrograde filling, of glomerular-shaped structures, deepest to the Schlemm canal was observed in the quadrants where the pathway was functioning. Our findings show that injection of a mixture composed of ICG and viscoelastic solution into the Schlemm canal allows a clear visualization of the functioning portions of the conventional outflow pathway. In addition, a retrograde filling of structures presumably located into the iris was also recorded.Clinical Trial Registration. Our study is registered in ISRCTN registry, number54005880, DOI 10.1186/ISRCTN54005880.

Download Full-text